Liminal BioSciences Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a LMNL research report →
Companywww.liminalbiosciences.com
Liminal BioSciences Inc. , a clinical-stage biopharmaceutical company, focuses on the development of novel small molecule drug therapeutics for inflammatory, fibrotic, and metabolic diseases in Canada and the United Kingdom. The company's lead product candidate is fezagepras (PBI-4050), which has been completed Phase I clinical trial for the treatment of idiopathic pulmonary, liver, cardiac, or skin fibrosis with fezagepras or related derivatives and respiratory diseases.
- CEO
- Bruce Pritchard BA, CA, FIOD
- IPO
- 2009
- Employees
- 251
- HQ
- Laval, QC, CA
Price Chart
Valuation
- Market Cap
- $27.62M
- P/E
- -0.03
- P/S
- 94.68
- P/B
- 0.03
- EV/EBITDA
- -0.07
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 100.00%
- Op Margin
- -8223.19%
- Net Margin
- -7210.97%
- ROE
- -73.35%
- ROIC
- -78.82%
Growth & Income
- Revenue
- $401.00K · -37.64%
- Net Income
- $-28,916,000 · 35.83%
- EPS
- $-341.80 · 35.83%
- Op Income
- $-32,975,000
- FCF YoY
- 68.18%
Performance & Tape
- 52W High
- $8.50
- 52W Low
- $3.10
- 50D MA
- $8.40
- 200D MA
- $6.20
- Beta
- 1.03
- Avg Volume
- 23.73K
Get TickerSpark's AI analysis on LMNL
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our LMNL Coverage
We haven't published any research on LMNL yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate LMNL Report →